[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-disease":698},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,45,75,109,135,164,189,210,239,261,286,317,342,370,397,428,462,488,514,536,565,593,624,645,680],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":4,"leadSponsor":41,"locationsCount":44},"100083273",false,"NCT00341237","Personalized Environment and Genes Study","* INCLUSION CRITERIA\n\nIn order to be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* Adults greater than or equal to 18 years of age\n* If female, must not be (self-reported as) pregnant. At the time of enrollment, a pregnancy test will only be done at the PI s discretion.\n* Able to understand and provide written informed consent\n* Able to come to the NIEHS Clinical Research Unit (CRU) for enrollment and study-related visits\u002Fprocedures.\n\nEXCLUSION CRITERIA\n\nAn individual who does not meet the inclusion criteria listed above is excluded from participation in this study.",true,"ALL","18 Years","120 Years",{"count":20,"type":21},25000,"ESTIMATED","OBSERVATIONAL","Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influence our environment, promoting health and decreasing the risk of disease. The Personalized Environment and Genes Study (PEGS) aims to determine how the environment and gene-environment interactions can inform our understanding of human health and disease. As science has evolved, so too has the science of this project. This evolution was reflected in a change in the title of this project from the Environmental Polymorphisms Registry (EPR) to the Personalized Environment and Genes Study (PEGS) to more accurately reflect the science that can be conducted. PEGS is a unique resource because of the depth of environmental phenotyping which includes extensive information from exposome surveys, as well as whole genome sequencing on a significant number of participants in the cohort. While it is small relative to genomic cohorts, none of these have the extensive environmental data that is present in PEGS. In addition, other cohorts with deep environmental data lack the depth of genomic data that is present in PEGS. Importantly, PEGS has already provided important analytic advances that are of great interest to and can be confirmed in larger cohorts such as All of Us.\n\nThe Personalized Environment and Genes Study (PEGS) aims to provide a resource for environmental health translational research by examining gene-environment interactions in health and disease. PEGS is an extension of two previous efforts where it began as a pilot study, the Environmental Polymorphisms Study (EPS; IRB# 02E9004) and was approved subsequently as a full protocol titled the Environmental Polymorphisms Registry (EPR) (IRB #04-E-N0053 and transitioned to its current ID# 04-E-0053). The EPR was envisioned as a phenotype-by-genotype registry of participants who had donated DNA samples, and who had agreed to be contacted for follow-up clinical translational studies based on their DNA genotypes. At the time, the only information available was a participant s age, sex, race, and ethnicity. Further phenotyping of a participant and\u002For any biospecimens obtained were investigated during a follow-up translational clinical study on participants recruited based on their genotype (hence phenotype-by-genotype) and the PEGS was the first recruit-by- genotype study at the NIH. Following a period focused on recruiting approximately 15,000 participants to enable genotyping of rare (approximately 1% minor allele frequency) single nucleotide polymorphisms (SNPs), the PEGS Consortium Project was undertaken in 2010- 2011 to examine, using the DNA of nearly 4,000 participants, approximately 700 SNPs in approximately 80 environmental response genes that work in concert with environmental exposures to elicit a phenotype. Several clinical follow-up studies, genotype-phenotype association studies, and publications have resulted from the PEGS Consortium Project.\n\nTo expand phenotype information available to researchers, the Health and Exposure Questionnaire was administered between 2013-2014. In 2017, a more detailed Exposome Questionnaire which includes questions relating to the external and internal exposome was administered. This was an important resource through which to integrate exposures with genotype-phenotype association studies.\n\nWhole genome sequencing has now been performed on approximately 4700 participants who were reconsented for this purpose, as indicated above. Questionnaire data was fully adjudicated and combined in a robust and searchable database. With the increased power of the data available, the project was renamed as the Personalized Environment and Genes Study (PEGS) and rolled out in Sept. 2021.",[25,26,27],"Diabetes","Heart Disease","Asthma",[29,30,31,32,33],"Genotype","Phenotype","Environmental Factor","Single Nucleotide Polymorphism","Natural History","RECRUITING","2026-06-27",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2010-05-26",{"name":42,"class":43},"National Institute of Environmental Health Sciences (NIEHS)","NIH",2,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100568003","NCT06675552","Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany","PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction (PHRASE-HF): A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care","PHRASE-HF","Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent\n* Hospitalised in a participating site and receiving full inpatient treatment (at least 24h hospital stay)\n* Diagnosis of HFrEF according to the current guidelines of the European Society of Cardiology (ESC) with a left ventricular EF of ≤40% (as measured per echocardiography during the index hospital stay or within 3 months prior to index hospitalisation with available reports from imaging (ejection fraction) at the time of study inclusion)\n* Treated with a maximum of 2 of the indicated drug classes (ACE-I\u002FARNI\u002FARB, BB, MRA, SGLT2i) according to guideline recommendation (GDMT) at admission.\n* Signed and dated written informed consent prior to enrolment in the study\n* Willing and capable to fulfil requirements listed in the ICF\n\nExclusion Criteria:\n\n* Initial presentation (index hospitalisation) in cardiogenic shock or other kinds of shock\n* Status post heart transplantation\n* History of intolerance to one or more GDMT drug classes (ACE-I\u002FARNI\u002FARB, BB, MRA, SGLT2i) or significant side effects that led to the discontinuation of two or more substances within one drug class (except from ACE-I\u002FARB, e.g., if 2 different ACE inhibitors triggered cough, but sartans are tolerated, then the patient is not excluded)\n* Current or planned participation in a clinical trial\n* Decision by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures\n* Pregnancy or breast-feeding","130 Years",{"count":54,"type":21},438,"Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial. Heart failure with reduced ejection fraction (HFrEF) represents approximately 50% of the HF patient population.The burden of HF is expected to increase substantially as the population ages, and despite improvements in treatment, hospitalisation and mortality rates remain especially high in HFrEF patients. The current guideline recommendation of directed medical therapy for HFrEF combines four drug classes with proven prognostic benefit: Angiotensin receptor-neprilysin inhibitor (ARNI)\u002Fangiotensin converting enzyme inhibitors (ACE I)\u002Fangiotensin receptor blockers (ARB), betablockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The 2023 ESC (European Society of Cardiology) HF guideline update additionally recommends a rapid in-hospital sequencing approach of guideline-directed medical therapy (GDMT) with frequent physician visits during the first 6 weeks post discharge. Studies investigating the implementation of GDMT in a real-world setting have shown that a significant proportion of patients did not receive the recommended drug combination therapy. Delayed initiation of GDMT contributes to the low number of patients receiving guideline concordant HFrEF therapy, which ultimately may affect patient outcomes. One approach to implement the 2023 ESC guideline updates for heart failure treatment regarding early in-hospital initiation and rapid up-titration of GDMT could be to provide specific training on GDMT recommendations. Such a standardised training is offered to the physicians treating HF patients within selected hospitals of the German Helios hospital network (Helios-GDMT-program). Evidence is needed in order to assess whether in-hospital initiation and up-titration of all phenotype concordant classes of GDMT at hospital discharge can be observed after standardised physician training and whether the GDMT-program implementation also translates into real-world routine outpatient care with respect to use of GDMT and clinical outcomes.",[26,57,58,59],"Heart Failure","Cardiovascular Disease","Heart Failure, Systolic",[61,62,63],"Heart Failure with Reduced Ejection Fraction (HFrEF)","Guideline Directed Medical Therapy","Real-World Evidence","2026-06-18",{"date":66,"type":38},"2026-06-22",{"date":68,"type":38},"2024-11-15",{"date":70,"type":21},"2027-06-30",{"name":72,"class":73},"AstraZeneca","INDUSTRY",6,{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100611457","NCT07240831","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring","PPG ABPM","Inclusion Criteria\n\n* Females and Males subjects 18 years or older (from all skin tones\u002Fcolors)\n* Scheduled for ABPM for hypertension screening, evaluation, or management\n* Subjects capable of using an application temporarily downloaded (for the duration of the study) on a personal smart phone device or on a device provided by the study sponsor\n* Subjects with Atrial fibrillation or Atrial flutter are eligible to participate if standard cuff-based ABPM monitor can capture blood pressure at initialization\n\nExclusion Criteria\n\n* Indication for ABPM is orthostatic hypotension or Postural Orthostatic Tachycardiac Syndrome as indicated on the ABPM referral order\n* Any neurological, psychological, or other condition impairing the ability to provide informed consent or participate in the study\n* Inability to reliably access the Internet via a smart phone\n* Not able to perform standard cuff-based ABPM\n* Average absolute difference between the two arms is greater than 15 mmHg for Systolic Blood Pressure (SBP) or greater than 10 mmHg Diastolic Blood Pressure (DBP) during the initialization\u002Fcalibration phase\n* Subjects with known allergy to adhesives or skin patches\n* Subjects with solid dark tattoos on the area where the PPG-based device is attached\n* Subjects who are unwilling to have their chest hair shaved, if needed, to install the device (the device uses adhesives and needs to be in direct contact with the skin without hair)\n* Subjects who are unwilling to comply with the study instructions (avoid vigorous exercise and showering for 24 hours while the device is in place)",{"count":83,"type":21},600,"INTERVENTIONAL",[86],"NA","This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake\u002FAsleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.",[89,26,90,91],"Blood Pressure","Hypertension (HTN)","Blood Pressure Monitoring",[93,94,90,95,96,97,98],"BLOOD PRESSURE","BLOOD PRESSURE MONITORING","CUFFLESS PHOTOPLETHYSMOGRAPHY","PPG","CUFFLESS","vital signs","2026-06-01",{"date":101,"type":38},"2026-06-02",{"date":103,"type":38},"2025-12-15",{"date":105,"type":21},"2026-10-30",{"name":107,"class":73},"Biobeat Technologies Ltd.",10,{"id":110,"slug":4,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":84,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100603013","NCT07130994","Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)","Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-septal TMVR System in Patients With Severe, Symptomatic Mitral Regurgitation (Cassini-US)","CASSINI-US","Inclusion Criteria:\n\n* Age 18 years or older.\n* Symptomatic, moderate to severe or severe, functional or mixed, mitral regurgitation (≥ Grade 3+).\n* NYHA functional Class ≥ II. If Class IV, patient must be ambulatory.\n* Ability to tolerate oral anticoagulation.\n* Ability to qualify for bailout surgery (which may include open heart surgery).\n* High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team.\n* Willing and able to complete study-related assessments and questionnaires.\n\nExclusion Criteria:\n\n* Purely degenerative (organic\u002Fprimary) (i.e. intrinsic valve lesions) mitral regurgitation.\n* Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement.\n* Life expectancy \\\u003C1 yr. due to noncardiac conditions.\n* Endocarditis in the 3 months prior to procedure date.\n* Current admission with acute heart failure exacerbation.\n* Dependency on inotropic agents or mechanical circulatory support.\n* Untreated clinically significant CAD.\n* Active systemic infection.\n* Modified Rankin Scale ≥4 disability.\n* Chronic renal failure defined as eGFR \\\u003C 30 mL\u002Fmin\u002Fm2 or on renal replacement therapy.\n* Severe pulmonary arterial hypertension (PAH), defined as PASP \\> 70mmHg.\n* Platelets \\\u003C 90,000.\n* COPD on home oxygen therapy deemed too high risk for intubation.\n* Refuses blood transfusions.\n* Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states).\n* Severe connective tissue disease under chronic immunosuppressive or cortisone therapy.\n* Participating in other investigational studies likely to confound the results or affect the study.\n* Unable or does not sign the study informed consent form.\n* Patients classified as \"vulnerable patients\"\n\nCardiovascular Exclusion Criteria\n\n* Myocardial infarction during prior 30 days.\n* Stroke or TIA during prior 90 days.\n* Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).\n* Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and\u002For anticipated mitral valve treatment prior to enrollment.\n* Prior surgical mechanical valve AVR.\n* Prior TAVI. -Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure.\n* CRT, CRT-D, IPG or ICD implanted in previous 30 days.\n* Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure \\\u003C90mmHg, Inotropic dependent or IABP\u002Fmechanical circulatory support.\n\nCABG or PCI within previous 30 days.\n\n* Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee.\n* Prior or planned heart transplantation (UNOS status 1).\n* Physical evidence of right-sided CHF:\n\n  1. Patients with ascites.\n  2. Patients with anasarca (generalized edema \u002F hydropsy).\n* Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy.\n\nProcedural Exclusion Criteria\n\n* Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).\n* Documented hypersensitivity to nickel or titanium.\n\nCardiac Imaging Exclusion Criteria (evaluated by Core Labs)\n\n* Contraindications to TEE imaging\n* Left ventricular EF ≤ 30% by echocardiogram.\n* Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.\n* Extensive mitral flail leaflets\n* Evidence of new or untreated intracardiac thrombus, mass, or vegetation.\n* Severe right ventricular dysfunction.\n* Severe tricuspid regurgitation.\n* Hemodynamically significant inter-atrial shunt (ASD).\n* Severe aortic regurgitation or aortic stenosis.\n* Anatomic ineligibility for SATURN Valve or SATURN TS procedure as determined by the Screening Committee.",{"count":117,"type":21},15,[86],"CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US).\n\nThe purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.\n\nPrimary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.",[121,26],"Mitral Regurgitation",[123,124,125],"Transcatheter","Mitral Valve","Replacement","NOT_YET_RECRUITING",{"date":101,"type":38},{"date":129,"type":21},"2026-06",{"date":131,"type":21},"2032-01",{"name":133,"class":73},"InnovHeart",5,{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100640624","NCT07591792","Outpatient Rehabilitation Programmes for Myocardial Ischemia, Heart Failure, and COPD: Satisfaction, Participation, Test Outcomes, and Factors Associated With Positive Changes in Test Results as Well as Level of Participation","Inclusion Criteria:\n\n* Patients from North Zealand Hospital (Hillerød and Frederikssund) referred with a rehabilitation plan for group-based rehabilitation for myocardial ischemia, heart failure, or COPD at North Zealand Hospital\n* Patient consent to participate in the project\n\nExclusion Criteria:\n\n* None",{"count":141,"type":21},840,"26 Weeks","Aim The aim of this project is to investigate the level of participation, satisfaction, changes in tests, and factors associated with these results in existing rehabilitation programmes at North Zealand Hospital and in the surrounding municipalities among patients with heart diseases and the lung disease chronic obstructive pulmonary disease (COPD). The project is conducted in clinical practice in a non-selected population.\n\nParticipants Individuals with heart disease and COPD who commence training at North Zealand Hospital. Up to 840 participants may be included over a two-year period. Participants will be recruited at the start of training at North Zealand Hospital.\n\nInclusion criteria:\n\nPatients from North Zealand Hospital (Hillerød and Frederikssund) referred with a rehabilitation plan for group-based rehabilitation for heart disease or COPD at North Zealand Hospital Patient consent to participate in the project. There are no exclusion criteria for the project.\n\nIntervention Participants will be invited to participate in the project when enrolling in the already existing group-based training programme lasting 6-10 weeks as part of rehabilitation for heart disease and COPD.\n\nData\n\nParticipation:\n\nNumber of patients commencing the training period relative to the number of patients referred from the cardiology department\n\nAttendance:\n\nNumber of completed training sessions relative to the total number of possible training sessions during the periods at the hospital and in the municipalities\n\nDropout:\n\nDropout during the hospital-based and municipality-based periods and reasons for dropout The data listed below will, as far as possible, be collected before and after the training period. Physical activity (the final variable) will additionally be measured three months after completion of the municipal programme.\n\n30-second sit-to-stand test\\* Six-minute walk test\\* Quality of life measured using the CAT questionnaire for COPD and EQ-5D for the two groups of patients with heart disease Musculoskeletal pain measured using a questionnaire with the Numeric Rating Scale for five body regions Physical activity measured using a modified version of the IPAQ questionnaire from the Danish Health and Morbidity Surveys\n\n\\*These tests are standard and implemented in the existing rehabilitation programmes.\n\nOther Data\n\nAdditional data will include:\n\nFrom questionnaire: educational level and BMI (height and weight) From patient records: age, sex, treatment for heart disease, and extent of other chronic diseases Data from patient records are already collected as part of routine clinical practice independently of this project.\n\nEthics Participants will be invited to the study with written and oral information. Participation will take place after informed consent. The study will be conducted in accordance with the regulations of the Scientific Ethical Committee, to which it will be submitted as soon as possible, and it will be reported in the Capital Region of Denmark's legal system via PRIVACY. The study will be registered in the project database www.clinicaltrials.gov. Data will be stored in the REDCap database system.\n\nDissemination of Results Results will be presented at local and regional meetings and symposia and published in international peer-reviewed scientific journals indexed in PubMed.",[26,145],"COPD",[147,145,148,149,150,151,152,153],"heart disease","Exercise training","Physical activity","Physical function","Quality of life","Muscoloskeletal pain","Adherence","2026-05-15",{"date":156,"type":38},"2026-05-19",{"date":158,"type":21},"2026-08-01",{"date":160,"type":21},"2029-06-30",{"name":162,"class":163},"Nordsjaellands Hospital","OTHER",{"id":165,"slug":4,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":15,"sex":16,"minAge":171,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":84,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100622178","NCT07380243","Pathways to Prevention Food-is-Medicine Trial","Health Care by Food Planning Grant","P2P","Inclusion Criteria:\n\n* Parent or legal guardian of school-aged child (ages 6 - 11 years of age)\n* Parent\u002Flegal guardian is 18 years or older and the primary caregiver at home\n* Parent and\u002For child has an eligible Medicaid insurance plan\n* Parent is able to read and speak English fluently\n* Parent has BMI greater than 30 kg\u002Fm\u002Fm\n* Ability to consume fruits and vegetables without concerns of any medication-nutrient interactions (for example, warfarin)\n\nExclusion Criteria:\n\n* Parent not a legal guardian or the primary caregiver\n* Non-English speakers\n* Parent or child is diagnosed with active metabolic or digestive illnesses that may result in nutrient malabsorption (Crohn's disease, Celiac, irritable bowel syndrome, food allergies, etc.).","6 Years",{"count":173,"type":21},120,[86],"The goal of this study is to learn whether combining healthy food access with personalized tools can help families improve heart health and make lasting lifestyle changes. The main questions the study aims to answer are:\n\n* Do the new tools (PRO-CVH and Triple-C) help families improve their heart health?\n* Which combination of tools and supports works best for families with limited access to healthy food?\n* Is this type of program easy to carry out and acceptable to families and healthcare teams?\n\nFamilies in the study will include one parent with a BMI greater than 30 who has Medicaid insurance and their child aged 6 to 11 years.\n\nDepending on which group they are assigned to, families may:\n\n* Receive food and nutrition education via handouts and\u002For online curriculum\n* Have access to an online health assessment tool than can help you understand your\u002Fyour child's risk factors for heart disease\n* Work with a personalized health coach who can help you set goals for healthier living online\u002Fvirtually.\n* Receive medically tailored groceries and cooking classes.\n\nResearchers will follow participants for several months to see how their heart health changes and which parts of the program work best together. The information from this study will help design a larger clinical trial to test a practical, cost-effective program that can help families build healthier habits and reduce their risk of heart disease.",[26,177],"Cardiovascular Health Status",[147,179],"cardiovascular","2026-05-13",{"date":154,"type":38},{"date":183,"type":38},"2026-02-26",{"date":185,"type":21},"2026-12-01",{"name":187,"class":163},"Amrik Singh Khalsa",1,{"id":190,"slug":4,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":84,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":188},"100619979","NCT07351656","A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound","Screening for Heart Disease Using AI-Enabled Electrocardiography and Focused Cardiac Ultrasound: the AI CVD Screen Study.","Adolescents and young adults:\n\nInclusion Criteria:\n\n* Enrollment in a high-school, college or a resident in MN during the study period\n* Age 15-29 years\n* Informed consent (and assent for minors)\n\nExclusion Criteria:\n\n* Presence of a pacemaker or defibrillator\n* Inability to obtain a quality ECG tracing\n\nCommunity dwelling adults:\n\nInclusion Criteria:\n\n• Adult patients (\\>30 years of age, with pre-specified subgroups 30-64 and 65+))\n\nExclusion Criteria:\n\n• Inability to provide informed consent to participate in the study\n\nPregnant women:\n\nInclusion Criteria:\n\n* Adult female aged 18 to 49 years\n* Pregnant at the time of enrollment\n* Receiving obstetric care at identified study site(s)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n• Inability to provide consent","15 Years",{"count":197,"type":21},19300,[86],"A study to evaluate feasibility, diagnostic yield, accuracy, and actionable thresholds of POC, immediate-feedback AI-ECG + AI FoCUS screening for cardiac disease in well described community populations.",[26],"2026-05-12",{"date":203,"type":38},"2026-05-14",{"date":205,"type":38},"2026-03-09",{"date":207,"type":21},"2028-02",{"name":209,"class":163},"Mayo Clinic",{"id":211,"slug":4,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":84,"phases":220,"briefSummary":221,"conditions":222,"keywords":227,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100614494","NCT07280325","Moxie Self-Management and Education Support Program","Moxie: A Self-management Education and Support Program Using Advertising Principles to Reduce Rehospitalization for Cardiovascular-related Illnesses","Inclusion Criteria:\n\nEligible participants will be adults aged 40-85 years who are being discharged to their home from general internal medicine or family medicine inpatient services (hospitalist) in one of 10 Alberta acute care facilities, whose admitting diagnosis was diabetes, coronary artery disease, heart failure, chronic kidney disease, or hypertension (see appendix for list of inclusion diagnoses).\n\nExclusion Criteria:\n\nIndividuals who live at the same address\u002Fhousehold as a person who is already in the study and\u002For those discharged from hospitals to continuing care facilities, rehabilitation facilities or another hospital will not be eligible to take part in the study. Individuals whose goals of care at the time of discharge from acute care were oriented towards comfort (i.e. C1 or C2 Goals of Care) will not be eligible to take part in the study. Individuals with markers indicating lack of competency\u002Fcapacity in their inpatient ConnectCare record such as anything but full capacity on the medical record (i.e. \"incapacitated\" or \"needs review\"), or presence of an alternative decision maker, agent, or legal guardian listed on the medical record.","40 Years","85 Years",{"count":219,"type":21},9000,[86],"Health education and self-management support are key facilitators of health behaviours. Moxie is a mixed media, self-management, education and support program for Albertans living with cardiovascular-related chronic conditions. Moxie is built upon our previous work within the ACCESS study (2015-21, n=4761), a RCT that previously tested the Moxie intervention in Alberta. Results demonstrated that MOXIE reduced the rate of hospitalizations (notably for hypertension, angina, hyper\u002Fhypoglycemia, heart failure decompensation, and acute kidney complications) by 34% in a population of low-income seniors living with cardiovascular-related chronic conditions.\n\nHowever, before Moxie can be effectively implemented province-wide, another trial is necessary to determine whether benefits can be observed in a larger cohort of patients with cardiovascular-related chronic conditions recruited immediately after hospital discharge (n=9000). Furthermore, the effectiveness of the two components of the ACCESS trial intervention will be assessed individually:\n\n(a) The Moxie Program, a tailored health and disease education component developed by a user-experience-centric design process incorporating patients, behavioural scientists, disease specialists, health system administrators and marketing\u002Fadvertising professionals; and (b) the facilitated relay of clinical information to healthcare providers (letters).\n\nThe trial is designed as a 2x2 factorial pragmatic, individual-level randomized pragmatic trial of these different interventions. This would yield the following groups:\n\n1. Moxie SMES Program\n2. Facilitated Relay\n3. Moxie SMES Program and Facilitated Relay\n4. True control\n\nSelf-management education and support (SMES) intervention: This includes weekly physical mailers sent directly to patients' homes throughout the study containing information about chronic conditions, medication use, diet, physical activity, smoking cessation, and self-management\u002Fwellness principles. These messages will be refined by the social impact creative design partner and reviewed by clinicians and patients to ensure clinical safety and appropriate tone. Weekly mailers will encourage participants to enroll and consent to participate in the digital program by scanning a QR code or accessing a website where they will sign up for their own personalized Moxie mobile health app, complete a digital consent form and opt-in for electronic delivery of Moxie messages.\n\nFacilitated relay intervention: Participants allocated to this intervention will receive letters by mail, one addressed to them, one to their primary care provider, and one to their pharmacist. The letters will not be sent to their primary care provider directly; rather, they will be sent to patients who will be encouraged to take them to their primary care provider and pharmacist should they decide to do so. We hope this will empower patients to start discussions with their healthcare providers. This also supports patient autonomy by enabling patients to decide whether they want to take them to their provider or not. If for whatever reason they do not feel that this is going to be beneficial or of interest, they are not required to do so. The letter would contain a note to the patient's healthcare provider stating that their patient is at-risk of cardiovascular disease and that evidence has shown that the pharmacotherapy is effective in improving outcomes for patients similar to the participant.\n\nThe primary outcome is readmission for cardiovascular-specific ambulatory care-sensitive conditions (ACSC) based on the most responsible diagnosis listed in CIHI Discharge Abstract Database-(DAD), using established algorithms within 12 months from randomization. This outcome includes all repeat admissions in the study period as recorded in the health record. This outcome is a count variable. We will calculate and compare each intervention arm's mean number and distribution of hospitalizations.",[223,224,26,225,226],"Chronic Kidney Disease","Diabetes (DM)","Stroke","Chronic Disease",[228,229,230],"Chronic Disease Self-Management","Pragmatic Trial","Chronic Disease Education","2026-05-08",{"date":233,"type":38},"2026-05-11",{"date":99,"type":21},{"date":236,"type":21},"2029-12-31",{"name":238,"class":163},"University of Calgary",{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":188},"100635855","NCT07558109","DigitHeart Echo Study","Cardiac Anatomical and Mechanical Properties Prediction From Electrocardiography (ECG) With Multi-Modal Representation Learning","DigitHeart-SHD","Inclusion Criteria:\n\n* aged ≥ 18 years old\n* planned to have echocardiography performed\n* voluntarily agree to participate in the trial.\n\nExclusion Criteria:\n\n* had echocardiography performed within 1 month\n* pacemaker rhythm on ECG\n* dextrocardia\n* complex adult congenital heart disease\n* ventricular assist device implantation.",{"count":247,"type":21},478,"Eligible patients will be interviewed by research staff to explain the trial design and rationale. Written informed consent will be obtained from patients who voluntarily agree to participate. Demographics and medical history will be obtained. A 12-lead ECG will be performed; it has not been performed within 6 months. A photo of the 12-lead ECG will be taken by research staff using the DigitHeart-2 smartphone application. Predictions from DigitHeart-2\u002FMERL-ECHO and other machine learning models hosted by the investigator team for each of the target anatomical and mechanical properties will be recorded. The cardiologist in charge of the patient, who is blinded to the prediction results from DigitHeart-2\u002FMERL-ECHO, will perform echocardiography according to American Society of Echocardiography guidelines, which will serve as the gold standard for accuracy evaluation.",[26,250,251],"Electrocardiograph","Echocardiography","2026-04-22",{"date":254,"type":38},"2026-04-30",{"date":256,"type":38},"2025-02-14",{"date":258,"type":21},"2027-02-14",{"name":260,"class":163},"The University of Hong Kong",{"id":262,"slug":4,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":84,"phases":270,"briefSummary":271,"conditions":272,"keywords":277,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":188},"100630289","NCT07485738","The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery","Surgical Measurement for Accurate Revascularization Using Transit-time FLOW (SMARTFLOW):Patency","SMARTFLOW","Inclusion Criteria:\n\n1. Age \\>18 years\n2. First-time, non-emergent isolated multivessel CABG through median sternotomy\n3. Willing and able to provide written informed consent and comply with all study procedures, including QOL questionnaires\n\nExclusion Criteria:\n\n1. Reoperation\n2. Emergency procedures\n3. Combined CABG + other cardiac or non-cardiac surgery\n4. Isolated single vessel CABG\n5. Minimally invasive CABG\n6. Inability to undergo coronary computed tomographic angiography (CCTA)\n7. Unable to provide written informed consent or comply with all the study procedures.",{"count":269,"type":21},1242,[86],"The purpose of this study is to learn more about a tool called Transit-Time Flow Measurement (TTFM). TTFM uses sound waves during surgery to check how well blood is flowing through blood vessels. This helps doctors see if the blood flow is good during coronary artery bypass grafting (CABG), which is a type of heart surgery",[273,274,275,276,26],"CABG Graft Integrity","CABG","Blood Flow","Transit-time Flow Measurement",[266],"2026-04-20",{"date":252,"type":38},{"date":281,"type":38},"2026-03-30",{"date":283,"type":21},"2032-03",{"name":285,"class":163},"Weill Medical College of Cornell University",{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":15,"sex":16,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":295,"conditions":296,"keywords":301,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":188},"100631593","NCT07502703","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥30 years\n2. Willing to participate and provide informed consent\n3. Able to undergo face scan, clinical examination, and laboratory testing\n\nExclusion Criteria:\n\n1. Facial abnormalities interfering with rPPG signal acquisition\n2. Inability to remain still during measurement\n3. Severe clinical instability\n4. Incomplete key variables","30 Years",{"count":294,"type":21},300,"The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.\n\nThe main questions it aims to answer are:\n\n1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements?\n2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?\n\nResearchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.\n\nParticipants will:\n\n1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system\n2. Receive standard clinical assessments, including blood pressure and heart rate measurements\n3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels\n\nThis study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.",[297,298,299,26,300,224],"Dyslipidemia","Angina (Stable)","Coronary Artery Disease (CAD)","Hypertension",[302,303,304,305,306,307,308],"remote photoplethysmography","rPPG","cardiovascular risk","ASCVD","Framingham score","digital health","screening tool","2026-04-15",{"date":278,"type":38},{"date":312,"type":21},"2026-04-23",{"date":314,"type":21},"2026-12-30",{"name":316,"class":163},"Tarumanagara University",{"id":318,"slug":4,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":84,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":44},"100624298","NCT07407816","Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure","Feasibility Study of the Supira System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (HRPCI) Who May Benefit From Mechanical Circulatory Support Beyond the PCI Procedure","Inclusion Criteria:\n\n* Subject has pre-existing heart failure, with NYHA Class II, III or IV prior to the index admission and documented LVEF ≤ 45%\n* Subject is presenting with one of the following criteria: unprotected left main coronary artery (ULMCA) disease, last patent vessel, or 3-vessel disease\n* Subject may benefit from hemodynamic support beyond the index procedure\n* Informed consent granted by the patient or legally authorized representative\n\nExclusion Criteria:\n\n* Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit\n* Aortic valvular disease or regurgitation categorized as moderate or greater (≥2+ on a 4-grade scale as assessed on TTE)\n* Aortic stenosis and\u002For aortic regurgitation categorized as moderate or greater (mean gradient \\>20 mmHg or valve area \\\u003C1.5 cm2 as assessed on TTE)\n* Presence of decompensated liver disease; severe liver dysfunction (Child-Pugh Score class C)\n* Ongoing renal replacement therapy with dialysis or continues renal replacement therapy\n* Heparin-induced thrombocytopenia, current or any prior occurrences\n* Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol\n* Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count ≤ 100,000\u002Fmm³ or spontaneous International Normalized Ratio (INR) ≥1.5 in the absence of medication or known fibrinogen ≤1.5 g\u002FL)\n* Breastfeeding or pregnant\n* Currently participating in active follow-up phase of another clinical study of an investigational drug or device\n* Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and\u002For to comply with study procedures","90 Years",{"count":325,"type":21},45,[86],"The objective of this study is to assess the safety and feasibility of the Supira System in heart failure patients with low LVEF, undergoing HRPCI with use of mechanical circulatory support who may benefit from cardiovascular hemodynamic support beyond the PCI procedure.",[26,329,57],"Coronary Arterial Disease (CAD)",[331,332],"Percutanous ventricular assist device","Supira System","2026-02-11",{"date":335,"type":38},"2026-02-17",{"date":337,"type":38},"2025-10-12",{"date":339,"type":21},"2027-05",{"name":341,"class":73},"Supira Medical",{"id":343,"slug":4,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":84,"phases":352,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":188},"100624949","NCT07416279","Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.","Intracardiac Pressures From Microbubbles Instead of a Catheter: First in Human Study and Signal Calibration","SonoHeart","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent to participate in the study\n* Patients who require a cardiac catheterisation procedure as part of their standard medical care\n* Good acoustic windows for echocardiography when lying flat on their back\n\nExclusion Criteria:\n\n* Known previous allergy to SonoVue, used in ultrasound contrast scans\n* Known allergy to any of the components of SonoVue microbubbles, for example, sulphur hexafluoride or polyethylene glycol (PEG), also known as macrogol, which is in bowel preparations used during colonoscopy and certain laxatives\n* A hole in their heart that lets blood flow from the right side to the left, skipping the lungs\n* Very high blood pressure in the arteries of the lungs (severe pulmonary hypertension)\n* Uncontrolled high blood pressure (hypertension)\n* Adult respiratory distress syndrome (ARDS; where severe lung inflammation prevents enough oxygen from reaching the body)\n* Current use of the medicine dobutamine (used to treat heart failure), or have been advised not to take dobutamine\n* Moderate to severe heart valve disease that could affect the catheter measurements\n* Recent acute coronary syndrome or unstable ischaemic cardiac disease, where blood flow to the heart muscle is reduced\n* Pregnant or may be pregnant\n* Participation in a clinical trial of a medicine within the past four months, to avoid any possible interactions with SonoVue\n* Participating in other research that would prolong their cardiac catheterisation procedure, to ensure that the overall process does not become too tiring or burdensome","21 Years","81 Years",{"count":108,"type":21},[86],"The goal of this clinical trial is to investigate if ultrasound contrast agents can be used to estimate filling pressures inside the heart in patients with suspected heart disease. The main questions it aims to answer are:\n\n* Is there a strong correlation between the contrast signal and filling pressures inside the heart?\n* What is the calibration approach to convert the contrast signal from dB to a measure of pressure in mmHg?\n\nResearchers will compare the contrast signal with reference pressures measured using a catheter to see if it can be used to quantify filling pressures inside the heart.\n\nParticipants will:\n\n* Be exposed to a small amount of additional ionising radiation to guide a catheter in position inside the heart for reference pressures\n* Receive an ultrasound contrast agent at the clinically recommended dose and in line with clinical guidelines, via an intravenous line in their arm\n* Undergo contrast echocardiography - ultrasound scan of their heart with contrast\n* Undergo standard echocardiography - ultrasound scan of their heart without contrast",[355,356,26],"HFpEF - Heart Failure With Preserved Ejection Fraction","Cardiac Catheterisation",[358,359,360,251],"Ultrasound contrast agents","Intracardiac filling pressures","Microbubble subharmonic signal","2026-02-10",{"date":363,"type":38},"2026-02-18",{"date":365,"type":21},"2026-02",{"date":367,"type":21},"2027-03",{"name":369,"class":163},"King's College London",{"id":371,"slug":4,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":84,"phases":378,"briefSummary":379,"conditions":380,"keywords":384,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":188},"100622802","NCT07388355","A Usability Study of a Multi-channel ECG Monitoring Device","WearLinq eWave Patch Study","Inclusion Criteria:\n\n* Adult \\>18 years old and able to consent\n* Capable of using a smartphone app\n* Willing to shave patch area if needed\n\nExclusion Criteria:\n\n* Planning to undergo an MRI during the study period\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results\n* Presence of pacemaker, ICD or other implanted electronic devices\n* Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest\u002Fsternum)\n* Pregnant or intending to become pregnant during the course of the study",{"count":377,"type":21},500,[86],"This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.",[381,26,382,383],"Healthy Adult Participants","Arrythmia","Cardiac",[385,386,387,388],"Electrocardiogram","ECG","EKG","Cardiac diagnostic","2026-01-29",{"date":391,"type":38},"2026-02-05",{"date":365,"type":21},{"date":394,"type":21},"2027-12",{"name":396,"class":73},"Wearlinq",{"id":398,"slug":4,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":404,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":134},"100451089","NCT05153967","Cooperative Assessment of Late Effects for SCD Curative Therapies","U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies","COALESCE","Inclusion Criteria\n\n* Confirmed laboratory diagnosis of SCD\n* Ability to give informed consent\n* Ability to provide pre- and post-curative therapy data\n* Treated with either one HSCT or with standard disease-modifying therapy\n\nExclusion Criteria\n\n•History of non-compliance","4 Years","65 Years",{"count":407,"type":21},750,"Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \\>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.",[410,411,412,26],"Sickle Cell Disease","Pulmonary Disease","Renal Disease",[414,415,416,417,418],"Myeloablative Autologous Gene Editing","Myeloablative Autologous Gene Therapy","Myeloablative allo-HSCT","Nonmyeloablative allo-HSCT","Disease-Modifying Therapy","2026-01-28",{"date":421,"type":38},"2026-01-30",{"date":423,"type":38},"2022-07-12",{"date":425,"type":21},"2027-02",{"name":427,"class":163},"Vanderbilt University Medical Center",{"id":429,"slug":4,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":84,"phases":437,"briefSummary":438,"conditions":439,"keywords":443,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":188},"100620186","NCT07354347","Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD","Optimal ATP Settings in the VT Zone for New Implantable Cardioverter Defibrillator (ICD) Implantation (DAN-ATP)","DAN-ATP","Inclusion Criteria:\n\n\\- ICD implantation for primary or secondary prophylactic indication\n\nExclusion Criteria:\n\n* None\n* Patients can actively opt out of participation in the study",{"count":436,"type":21},3980,[86],"This is a pragmatic, two-group, cluster randomized trial designed to compare strategies for the Anti Tachycardia Pacing (ATP)-setting in the ventricular tachyarrhythmias (VT) zone when implanting a new implantable cardioverter defibrillator (ICD) in patients with heart disease in hospitals in Denmark.\n\nThe strategies are: \"Burst\" or \"Ramp\" after 1. ATP (which is always burst) in VT zone. VT zone is defined between 180-249 (up to 269 in special cases) heartbeats per minute.\n\nThe ICD will give either:\n\nBurst: The ICD is programmed to give ATP with 4 bursts. Or Ramp: The ICD is programmed to give ATP with 1 burst and 3 ramps.\n\nThe participating hospitals will be assigned to one of two intervention strategies for periods of 4-months. The given intervention will follow the patient\u002FICD throughout the life time of the ICD, but with the possibility to reprogram at any time (intention to treat).\n\nIt is calculated that the study needs a total of 398 events (second to fourth ATP), which is estimated to require 3980 implanted ICDs. The participants will be followed until the end of the ICD life, which is estimated to be around 10 years.",[26,440,441,442],"Implantable Cardioverter Defibrillator (ICD)","Heart Rhythm Disorders","Ventricular Tachyarrhythmias",[444,445,446,447,448,449,450,451,452],"Heart failure","ICD","ATP","Anti Takykardi Pacing","Implantable Cardioverter Defibrillator","cluster randomisation","heart rhythm disorder","ventricular tachyarrhythmias","VT","2026-01-26",{"date":455,"type":38},"2026-01-27",{"date":457,"type":21},"2026-02-01",{"date":459,"type":21},"2041-07-31",{"name":461,"class":163},"Rigshospitalet, Denmark",{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":84,"phases":471,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":487},"100587388","NCT06927739","Focused Orticumab Research for Treating Inflammation in Coronary Arteries","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA","FORTIFY","Inclusion Criteria:\n\n1. Participant must provide informed consent before any study specific activities are performed, must be able and willing to meet all requirements for randomization and must adhere to the schedules of activities.\n2. Participant must be \\>180 days after presumed type-1 myocardial infarction (i.e., due to plaque rupture or erosion, either STEMI or NSTEMI) without subsequent unstable or severe angina (Canadian Cardiovascular Society Class 3 or 4) at the time of enrollment. Participants who have undergone PCI are allowed.\n3. Participant must be on a stable cardiovascular treatment regimen consistent with local treatment guidelines for post-AMI patients (such as maximally tolerated statin and\u002For PCSK9 inhibitor medication for LDL reduction, antiplatelet medication, and hypertension treatment).\n4. Participant must have an evaluable, pre-randomization CCTA with one of the following:\n\n   1. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 50th centile (per reference standard) for their age group in at least two coronary arteries or\n   2. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 75th centile (per reference standard) for their age group in at least one coronary artery\n5. Participant must have body mass index (BMI) ≤ 40 kg\u002Fm2.\n6. Adult male and female participants ≥18 years of age at the Screening Visit:\n\nFor female participants, the participant must not be pregnant or lactating and must be one of the following:\n\n1. Postmenopausal, defined as amenorrhea for ≥ 12 months following cessation of all exogenous hormonal treatments; follicle stimulating hormone levels may be obtained at the investigator's discretion to confirm the participant is postmenopausal.\n2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilization.\n3. Females of childbearing potential must have a negative serum or urine pregnancy test prior to the start of study drug. In the case of positive urine pregnancy testing, a negative serum sample for pregnancy testing, to confirm that the participant is not pregnant, must be obtained prior to start of study. They must also agree to use an adequate method of contraception from Baseline through the End of the study or for 30 days after the last dose of study drug (whichever is longer), which include the following: sexual abstinence (if preferred and usual lifestyle of the participant), condom with spermicidal gel, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depo progesterone injections, progesterone implant (i.e., Implanon®), NuvaRing®, Ortho Evra®.\n\nFor male participants - Nonsterile male participants with sexual partners of childbearing potential must agree to use an adequate method of contraception, including sexual abstinence (if preferred and usual lifestyle of the participant), from Baseline through the End of the study.\n\nExclusion Criteria:\n\n1. History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n2. Percutaneous coronary intervention or invasive diagnostic coronary angiogram planned after screening. Eligible participants who have an invasive diagnostic coronary angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.\n3. History of or planned coronary artery bypass grafting.\n4. Documented episode of post-MI pericarditis in the 3 months before enrollment.\n5. Presence of unstable or uncontrolled angina. Canadian CV society (CCS) angina class \\> 2.\n6. Ongoing New York Heart Association Class IV HF.\n7. Poorly controlled type 1 or type 2 diabetes mellitus (hemoglobin A1c \\>8.0%).\n8. Increased risk of bleeding:\n\n   1. With history or presence of any bleeding disorder.\n   2. Signs of ongoing bleeding at screening (e.g., identified macroscopic bleeding, low hemoglobin presumed to be caused by bleeding) or high risk for major bleeding in accordance with the Investigator's assessment (participants taking clinically indicated antiplatelet and antithrombotic agents are acceptable).\n   3. Known severe liver disease (e.g., \\>5´ upper limit of normal elevations in ALT and\u002For AST and other evidence of grade 3 or higher criteria applies such as from the CTCAE 5.0 guidelines).\n9. History or presence of any of the following:\n\n   1. Ongoing infection or febrile illness.\n   2. Ongoing persistent or permanent atrial fibrillation or flutter.\n   3. Cancer within 5 years before randomization, with the exception of non-melanoma skin cancer.\n   4. Alcohol or substance abuse within 6 months before randomization, as judged by the investigator.\n   5. Known history of hypersensitivity reactions to other biologics, to human IgG preparations, or to any component of orticumab, or ongoing severe allergy as judged by the investigator.\n   6. Active positive results on screening for serum hepatitis C core antibody.\n   7. Clinically documented hepatitis B or HIV.\n10. Any clinically important abnormalities in clinical chemistry, hematology, coagulation parameters, as judged by the investigator.\n11. Blood pressure values at screening (taken as the average of triplicate measurements):\n\n    1. Systolic blood pressure \\\u003C 90 mmHg or \\> 180 mmHg.\n    2. Diastolic blood pressure \\> 100 mmHg.\n    3. One triplicate retest (repeat of all 3) will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized\n    4. Participants who are excluded based on elevated blood pressure may be rescreened following adequate treatment.\n12. Participants with any of the following contraindications to CCTA.\n\n    1. eGFR \\\u003C 40 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, or end stage renal disease treated with kidney transplant or renal replacement therapy.\n    2. Allergy to iodinated contrast.\n    3. History of contrast-induced nephropathy.\n    4. Contraindication to nitroglycerin.\n    5. Rapid heart rate that is uncontrolled by medical therapy.\n    6. Inability to hold breath for at least 6 seconds.\n13. Use of any of the following in the 180 days before randomization: IL-17 inhibitor, TNF inhibitor, IL-6 inhibitor, IL-1β inhibitor, methotrexate, cyclosporine, apremilast, colchicine, systemic steroids (topical steroid use is allowed).\n14. COVID-19 vaccine within 90 days of screening CCTA.\n15. Participants with a confirmed positive COVID-19 test within 90 days of screening CCTA.\n16. Receipt of any investigational device or therapy within 6 months or 5 half-lives before screening (whichever is longer).\n17. Planned participation in an additional investigational study of an intervention or biologic before the end of the follow-up period. Participation in observational studies or studies without investigational drugs or devices is allowed.\n18. Participants who have previously been exposed to orticumab.\n19. Participants who are legally institutionalized.\n20. An employee or close relative of an employee of the sponsor, the CRO, or the study site, regardless of the employee or close relative's role.",{"count":470,"type":21},240,[472],"PHASE2","The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:\n\nClinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA\n\nResearchers will compare the effects with placebo group after 6 months of treatment\n\nParticipants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies",[475,329,476,26,477,478],"Acute Coronary Syndromes","Inflammation","Myocardial Infarct","Atherosclerotic Coronary Vascular Disease","2026-01-24",{"date":455,"type":38},{"date":482,"type":38},"2025-08-11",{"date":484,"type":21},"2027-06-01",{"name":486,"class":73},"Abcentra",41,{"id":489,"slug":4,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":16,"minAge":495,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100622045","NCT07378514","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)","EVOLVE","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Willing to comply with study procedures.\n3. The participant must present as one of the following cohorts (primary presenting condition):\n\n   * Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)\n   * Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)\n   * Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)\n   * Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)\n   * Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)\n   * Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)\n   * Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )\n   * Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).\n\nInclusion Criteria for Cohorts A, B, C, D, E, G, and H:\n\n1\\. Participants ≥ 18 years of age\n\nInclusion Criteria for Cohort F (Diabetes Cohort):\n\n1\\. Participants ≥ 16 years old\n\nExclusion Criteria:\n\n1. Subjects deemed inappropriate for the study by the Principal Investigator.\n2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days.\n\nExclusion Criteria for Cohort E (Oral Anticoagulation Cohort):\n\n1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.\n2. Subjects who have anti-phospholipid antibody syndrome (APS)\n3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.","16 Years",{"count":497,"type":21},30000,"This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.\n\nApproximately 30,000 patients are expected to participate in this study, across multiple UK sites.",[500,501,26,502,503,25,504,505],"Blood Clots","Infection and Inflammatory Reaction","Kidney Disease","Vitamin K Antagonist","High Cholesterol","Liver Disease","2026-01-22",{"date":421,"type":38},{"date":509,"type":21},"2026-04",{"date":511,"type":21},"2031-07",{"name":513,"class":73},"LumiraDx UK Limited",{"id":515,"slug":4,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":532,"leadSponsor":534,"locationsCount":188},"100609420","NCT07214350","Sex Differences in Barriers and Participation in Physical Activity During and Following Cardiac Rehabilitation","SPARC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Enrolled in cardiac rehabilitation within the last month\n* Own a smartphone or tablet for mobile application download\n\nExclusion Criteria:\n\n* Planned relocation during the study period out of the local area\n* Planned medical procedure within the study period that may limit physical activity (i.e., joint replacement)\n* End-stage kidney disease\n* Impairment from stroke, injury, or other medical conditions that would prevent participation in or completion of the protocol\n* Heart transplant\n* Use of a left ventricular assist device\n* Pregnant or intending to become pregnant during the study period\n* Any other illness that, in the opinion of the study physician, would negatively impact or mitigate participation in or completion of the protocol",{"count":521,"type":21},150,"The SPARC study will measure physical activity and functional fitness during cardiac rehabilitation, right after completion of cardiac rehabilitation, and 6 months later. This will help investigators learn if men and women maintain physical activity levels and functional fitness differently during and after they complete cardiac rehabilitation. Participants in this study will have three in-person study visits and may complete two qualitative interviews over a 10-month study period. The greatest risks during the study include physical discomfort, falling, and\u002For shortness of breath during the fitness testing.",[524,26],"Cardiac Rehabilitation",[526,527],"Physical Activity","Sex Differences","2025-12-02",{"date":530,"type":38},"2025-12-03",{"date":528,"type":38},{"date":533,"type":21},"2030-08",{"name":535,"class":163},"Duke University",{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":84,"phases":545,"briefSummary":546,"conditions":547,"keywords":551,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":188},"100602674","NCT07126587","Healthy Living Anson Study","Healthy Living Anson","HLA","Inclusion Criteria:\n\n* Potential participants must be a resident of Anson County.\n* At least 18 years of age.\n* Have or be at risk for a chronic disease.\n* Ability to make own dietary decisions.\n* Ability to travel to a central Anson County location for data collection and group class sessions.\n* Ability and willingness to try the prepared meals.\n* Ability to store 10 frozen meals in a freezer.\n* Ability to communicate in English\n* No dietary restrictions or food allergies such that a Mediterranean diet is not appropriate.","99 Years",{"count":173,"type":21},[86],"The goal of this randomized delayed control intervention research study is to see if participants who receive education and healthy prepared meals improve the quality of their diet compared to participants who receive only physical activity education and coaching.",[548,549,26,300,550,504],"Obesity (Disorder)","Diabetes Type 2","Cancer",[540,552,553,554,555],"HLA study","nutrition","healthy eating","overweight (BMI ≥ 25)","2025-10-29",{"date":558,"type":38},"2025-10-30",{"date":560,"type":38},"2025-09-24",{"date":562,"type":21},"2028-03-30",{"name":564,"class":163},"University of North Carolina, Chapel Hill",{"id":566,"slug":4,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":15,"sex":16,"minAge":171,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":84,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":188},"100561956","NCT06596902","Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions","AFL","Inclusion Criteria:\n\n* parents aged ≥18 years\n* children aged 6-11 years\n* living in the target community (within 5 miles of one of targeted community centers)\n\nExclusion Criteria:\n\n* for the parent or child are presence of a medical or physical condition that is contraindicated to participating in sports\u002Fexercise (e.g., negative score on the Physical Activity Readiness Questionnaire (PAR-Q)).",{"count":572,"type":21},290,[86],"This study has the goal to increase physical activity and fitness among Latinos in San Diego, California and Mexicali, Baja California (U.S.-Mexico border) since these cities have similar diseases such as high rates of heart disease and obesity. Therefore there is a need to have physical activity programs for children and their families. We will collaborate with community centers to have this program available.",[576,26],"Obesity Prevention",[578,579,580,581,582,583],"Fitness","Healthy Lifestyle","Community Based","Family Program","Latino","U.S.-Mexico Border","2025-09-30",{"date":586,"type":38},"2025-10-06",{"date":588,"type":38},"2024-06-24",{"date":590,"type":21},"2029-01",{"name":592,"class":163},"San Diego State University",{"id":594,"slug":4,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":600,"targetDuration":602,"studyType":22,"phases":4,"briefSummary":603,"conditions":604,"keywords":610,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":188},"100571925","NCT06726590","Interprofessional Pharmacogenomics (IPGx) Registry and Repository","The Texas Interprofessional Pharmacogenomics Registry and Repository","IPGx Registry","Inclusion Criteria:\n\n* The study will invite patients who are eligible for PGX workup\u002FPGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or\n* Individuals taking blood pressure or depression medications, even if less than five medications.\n* Ability to understand and give consent.\n* Able to consent to donate blood and\u002For urine samples and buccal swabs.\n* Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.\n* Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.\n* All genders.\n* Any age over 18 years.\n\nExclusion Criteria:\n\n* Individuals admitted to hospice.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,\n* Individuals who are unable or unwilling to provide consent.\n* Unable to verbally communicate and comprehend English language",{"count":601,"type":21},3000,"6 Months","This program collects genetic and health information to help doctors choose the right medications for patients.",[25,605,550,606,26,607,145,608,609],"Cholesterol","Blood Pressure Disorders","Respiratory Ilness","Adverse Drug Reaction (ADR)","Poly Pharmacy",[611,612,613,614],"REGISTRY","REPOSITORY","POLYPHARMACY","ADVERSE DRUG REACTION","2025-09-05",{"date":617,"type":38},"2025-09-12",{"date":619,"type":21},"2025-11",{"date":621,"type":21},"2029-11",{"name":623,"class":163},"Texas A&M University",{"id":625,"slug":4,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":188},"100579985","NCT06831409","Using CTA Measures to Define Cardiac Risk In NFL Alumni","GAMEFILM","Inclusion Criteria:\n\n* Retired NFL player\n\nExclusion Criteria:\n\n* CCTA not successfully processed for FFRct and AI-Plaque",{"count":294,"type":21},"The GAMEFILM Registry is a post-market, multi-center, data collection study assessing the presence of CAD in NFL alumni.",[299,26,633],"Coronary Atherosclerosis",[635,26],"NFL","2025-08-25",{"date":638,"type":38},"2025-08-26",{"date":640,"type":38},"2024-12-17",{"date":642,"type":21},"2026-12-31",{"name":644,"class":73},"HeartFlow, Inc.",{"id":646,"slug":4,"hasResults":11,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":84,"phases":653,"briefSummary":655,"conditions":656,"keywords":666,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":676,"leadSponsor":678,"locationsCount":4},"100601897","NCT07116473","To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)","A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)","Key Inclusion Criteria:\n\nParticipants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM).\n\nKey Exclusion Criteria:\n\n1. Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only, or who permanently discontinued study drug prior to diagnosis of ATTR-CM in AG10-501.\n2. History of AL or another non-TTR amyloid subtype (eg, ApoA-1, gelsolin).\n3. History of a monoclonal paraprotein or abnormal light chains in serum or urine (i.e., MGUS) in which AL has not been ruled out.\n4. Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL\u002Fmin\u002F1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.\n5. Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 after documentation with the Medical Monitor.\n6. History of any organ transplant (with the exception of corneal transplant).\n7. Known hypersensitivity to acoramidis or any of the excipients within the study drug.\n8. Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product.",{"count":652,"type":21},250,[654],"PHASE3","The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).",[657,658,659,660,661,26,662,663,664,665],"Amyloidosis in Transthyretin (TTR)","Amyloidosis, Familial","Amyloid Cardiomyopathy","Amyloid Cardiomyopathy, Transthyretin-Related","Amyloidogenic Transthyretin (ATTR) Amyloidosis","Cardiomyopathies","Amyloidosis, Hereditary, Transthyretin-Related","Polyneuropathies","Amyloidosis",[667,668,665,669,670,671,672],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","Hereditary","2025-08-07",{"date":482,"type":38},{"date":619,"type":21},{"date":677,"type":21},"2037-12",{"name":679,"class":73},"Eidos Therapeutics, a BridgeBio company",{"id":681,"slug":4,"hasResults":11,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":11,"sex":16,"minAge":405,"maxAge":4,"enrollmentInfo":685,"targetDuration":602,"studyType":22,"phases":4,"briefSummary":686,"conditions":687,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":695,"leadSponsor":696,"locationsCount":188},"100602124","NCT07119424","Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study;\n2. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.\n3. The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;\n4. Age ≥65 years;\n5. Participant has not yet started the prescribed SGLT2i therapy;\n6. Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.\n\nExclusion Criteria:\n\n1. Current or previous use of SGLT2i;\n2. Inability to sign the informed consent.",{"count":294,"type":21},"The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.",[688,224,26,689,690],"Elderly Patients (>65 Years)","Renal Diseases","Internal Disease","2025-08-05",{"date":693,"type":38},"2025-08-13",{"date":256,"type":38},{"date":425,"type":21},{"name":697,"class":163},"Chiara Lanzani",""]